We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
A summary of recent letters and notifications sent to healthcare professionals about medicines, and a patient safety alert on mexiletine hydrochloride.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
Using an ecological momentary assessment to evaluate your digital health product.
Product Safety Report for Esapharma Movate Steroid Cream presenting a serious chemical risk.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Letters were sent about alemtuzumab (Lemtrada), Selenase (sodium selenite pentahydrate), and Erelzi▼ (etanercept).
Incident planning for potent synthetic opioids arriving into the illicit drug market.
Reference documents for collecting and inputting data, for use with the national drug treatment monitoring system (NDTMS).
Check the tariff classification for surface-active preparation for washing the skin and the hair (gel 2-in-1).
Change to the information provided on adverse events in the Summary of Product Characteristics (SPC).
Product Safety Report for SIVOP Parfums & Cosmétiques Clair-Liss Lightening Body Cream presenting a serious chemical risk.
Product Safety Report for Vixa Skineal Steroid Cream presenting a serious chemical risk.
medac GmbH (t/a medac Pharma LLP) is recalling the products and respective batches in this notification due to pink discolouration of the dacarbazine solution immediately after reconstitution (after correct preparation and storage).
Tofacitinib should not be used in patients older than 65 years of age, people who are current or past smokers, or individuals with other cardiovascular (such as diabetes or coronary artery disease) or malignancy risk factors unless there are no...
Explanation of the personal information collected as part of UKHSA's enhanced Yersinia surveillance, how we use it and who we share it with.
Guidance on acetic acid (also known as ethanoic acid) for use in responding to chemical incidents.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.